Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Earnings of $0.67 Per Share

Share on StockTwits

Wall Street brokerages expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of $0.67 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.79 and the lowest is $0.42. Neurocrine Biosciences posted earnings per share of $0.52 during the same quarter last year, which would suggest a positive year over year growth rate of 28.8%. The company is expected to issue its next quarterly earnings report on Monday, November 4th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $0.80 per share for the current fiscal year, with EPS estimates ranging from $0.40 to $0.98. For the next year, analysts expect that the firm will post earnings of $3.36 per share, with EPS estimates ranging from $1.94 to $4.68. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, July 29th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.13. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The business had revenue of $183.58 million for the quarter, compared to analyst estimates of $161.79 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. Neurocrine Biosciences’s revenue was up 89.5% on a year-over-year basis.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a report on Wednesday, July 31st. Oppenheimer assumed coverage on Neurocrine Biosciences in a report on Tuesday, July 16th. They set an “outperform” rating and a $100.00 target price on the stock. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, July 31st. Guggenheim assumed coverage on Neurocrine Biosciences in a report on Tuesday, June 4th. They set a “neutral” rating and a $88.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $107.15.

In other news, insider Haig P. Bozigian sold 19,297 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $85.02, for a total value of $1,640,630.94. Following the transaction, the insider now owns 161,273 shares of the company’s stock, valued at $13,711,430.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Haig P. Bozigian sold 17,268 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $82.62, for a total value of $1,426,682.16. Following the completion of the transaction, the insider now directly owns 157,812 shares in the company, valued at approximately $13,038,427.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 211,897 shares of company stock worth $19,536,555. Company insiders own 4.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of NBIX. Evolution Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $40,000. Capital Investment Advisory Services LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $43,000. NEXT Financial Group Inc grew its position in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock valued at $47,000 after purchasing an additional 265 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock valued at $51,000 after purchasing an additional 246 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of Neurocrine Biosciences by 9,242.9% in the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after purchasing an additional 647 shares during the last quarter. 94.45% of the stock is currently owned by institutional investors.

NBIX opened at $97.59 on Friday. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The firm has a market capitalization of $8.91 billion, a PE ratio of 443.59, a PEG ratio of 5.06 and a beta of 1.32. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.44. The business’s 50-day simple moving average is $91.19 and its 200 day simple moving average is $84.60.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: Special Dividends

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jack Henry & Associates, Inc.  Short Interest Update
Jack Henry & Associates, Inc. Short Interest Update
Carriage Services, Inc.  Short Interest Down 6.4% in August
Carriage Services, Inc. Short Interest Down 6.4% in August
Ingles Markets, Incorporated  Short Interest Down 6.3% in August
Ingles Markets, Incorporated Short Interest Down 6.3% in August
Mdu Resources Group Inc  Sees Significant Decline in Short Interest
Mdu Resources Group Inc Sees Significant Decline in Short Interest
Edwards Lifesciences Corp  Sees Large Decline in Short Interest
Edwards Lifesciences Corp Sees Large Decline in Short Interest
Short Interest in Fox Corp  Declines By 6.1%
Short Interest in Fox Corp Declines By 6.1%


© 2006-2019 Ticker Report